186 related articles for article (PubMed ID: 29868909)
1. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
4. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
Dultz G; Gerber L; Zeuzem S; Sarrazin C; Waidmann O
J Viral Hepat; 2016 Apr; 23(4):267-73. PubMed ID: 26554542
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
[TBL] [Abstract][Full Text] [Related]
7. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
8. Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
Reid M; Ma Y; Scherzer R; Price JC; French AL; Plankey MW; Grunfeld C; Tien PC
AIDS; 2017 Jan; 31(3):385-393. PubMed ID: 28081037
[TBL] [Abstract][Full Text] [Related]
9. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
[TBL] [Abstract][Full Text] [Related]
10. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
11. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.
Björklund J; Laursen TL; Sandahl TD; Møller HJ; Vilstrup H; Ott P; Grønbæk H
Orphanet J Rare Dis; 2018 Sep; 13(1):169. PubMed ID: 30241550
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected women.
Kuniholm MH; Hanna DB; Landay AL; Kaplan RC; Ley K
Hepatology; 2015 Feb; 61(2):734-5. PubMed ID: 25044447
[No Abstract] [Full Text] [Related]
13. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women.
French AL; Grennan D; Daubert E; Seaberg EC; Peters M; Augenbraun M; Fischl M; Kassaye S; Franco R; Kuniholm M; Adimora AA; Workowski K; Weber KM
AIDS; 2021 Jul; 35(9):1433-1438. PubMed ID: 33710024
[TBL] [Abstract][Full Text] [Related]
14. The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
Cairoli V; De Matteo E; Casciato P; Ameigeiras B; Preciado MV; Valva P
PLoS One; 2022; 17(7):e0270911. PubMed ID: 35797388
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
16. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
17. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
Beltrán LM; Muñoz Hernández R; de Pablo Bernal RS; García Morillo JS; Egido J; Noval ML; Ferrando-Martinez S; Blanco-Colio LM; Genebat M; Villar JR; Moreno-Luna R; Moreno JA
PLoS One; 2014; 9(3):e90541. PubMed ID: 24594990
[TBL] [Abstract][Full Text] [Related]
18. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.
Knudsen TB; Ertner G; Petersen J; Møller HJ; Moestrup SK; Eugen-Olsen J; Kronborg G; Benfield T
J Infect Dis; 2016 Oct; 214(8):1198-204. PubMed ID: 27354366
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy.
Burdo TH; Lentz MR; Autissier P; Krishnan A; Halpern E; Letendre S; Rosenberg ES; Ellis RJ; Williams KC
J Infect Dis; 2011 Jul; 204(1):154-63. PubMed ID: 21628670
[TBL] [Abstract][Full Text] [Related]
20. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
